SenesTech Inc (NASDAQ:SNES) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus target price of $2.50 for the company and are predicting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given SenesTech an industry rank of 155 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut shares of SenesTech from a “hold” rating to a “sell” rating in a report on Friday, November 16th.
Shares of SNES traded up $0.01 during mid-day trading on Friday, hitting $0.65. The company’s stock had a trading volume of 23,315 shares, compared to its average volume of 84,300. The stock has a market capitalization of $13.73 million, a P/E ratio of -0.58 and a beta of 0.38. The company has a debt-to-equity ratio of 0.03, a current ratio of 9.02 and a quick ratio of 7.88. SenesTech has a fifty-two week low of $0.30 and a fifty-two week high of $2.37.
SenesTech (NASDAQ:SNES) last announced its quarterly earnings data on Monday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). The business had revenue of $0.11 million during the quarter. SenesTech had a negative return on equity of 169.43% and a negative net margin of 6,510.67%. As a group, equities research analysts forecast that SenesTech will post -0.66 EPS for the current fiscal year.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.